BioSpace News Archive

a Zealand Pharma A/S, a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced the appointment of pharmaceutical industry veterans Enrique Conterno and Elaine Sullivan as observers to the company’s board of directors.

Jasper Therapeutics, Inc. today announced that the first patient has been dosed in Jasper’s phase 1b/2a clinical study of subcutaneous briquilimab for the treatment of CSU called BEACON (a phase 1b/2a Briquilimab dose Escalation trial assessing ACtivity, safety, and pharmacOkinetics iN adult patients with chronic spontaneous urticaria).

Nautilus Biotechnology, Inc. today announced Nautilus co-founder and Chief Scientist Parag Mallick, Ph.D., was selected as the 2024 recipient of the Gilbert S. Omenn Computational Proteomics Award presented by the US Human Proteome Organization (US HUPO).

Ocuphire Pharma, Inc. today announced that the Company’s CEO, George Magrath M.D., M.B.A., M.S., will deliver a presentation at the Ophthalmology Innovation Summit (OI S X III), to take place in San Diego, CA on December 1-2, 2023.

Belite Bio, Inc today announced that it will be participating at the Benchmark Company’s 12th Annual Discovery One-on-One Investor Conference to be held Thursday, December 7, 2023, at the New York Athletic Club in New York City.

Partner Therapeutics, Inc. (PTx) announced today that the European Respiratory Journal published the results of a prospective, randomized clinical trial of Leukine.

Today Scantox, together with its majority owner Impilo, has agreed to acquire the neuropharmacology division of QPS Austria GmbH (“QPS Neuro” or “the Company”) ultimately owned by QPS Holdings LLC.

Presage Biosciences has entered into an agreement with AstraZeneca (LSE/STO/Nasdaq: AZN), a global biopharmaceutical company.

Vizgen today announced an expansion of its leadership team with the appointment of two highly accomplished industry leaders.

Everest Medicines reported positive topline data results from a multi-center Phase 3 clinical trial of etrasimod in Asia for the treatment of moderate-to-severe active ulcerative colitis.